Preventive healthcare has traditionally offered the same advice for almost everyone: eat well, stay active, avoid smoking, and get your annual check-up.
This remains valuable advice, but it does not account for the significant differences between individuals.
Personalised medicine is beginning to change this approach. Genetic risk scores, biomarker testing and continuous health data can help clinicians understand not only which factors generally increase the risk of disease, but who may be more vulnerable and when to intervene.
This represents a genuine move towards more precise prevention, but it does not guarantee better outcomes for every individual.
A genetic risk score or biomarker result may help identify who could benefit from earlier screening, but its value depends on appropriate clinical interpretation and what happens next.
What Is Personalised Medicine, in the Context of Prevention?
Personalised medicine, also known as precision medicine, uses information about an individual’s genetics, biology and lifestyle to guide prevention and treatment, rather than relying entirely on recommendations based on population averages, which may not always reflect an individual’s level of risk or health needs.
In practice, this may involve combining established clinical information, such as blood pressure, cholesterol levels and family history, with newer tools such as polygenic risk scores.
These scores combine information from multiple genetic variants to estimate someone’s inherited risk of conditions including breast cancer or type 2 diabetes.
It follows the same principle explored when looking beyond one general measure to understand what may be happening within the individual.
The difference is that this information may be applied earlier, before symptoms appear.
What Personalised Medicine Gets Right
A 2026 analysis modelled polygenic risk score-based screening across seven commonly screened conditions, abdominal aortic aneurysm, breast cancer, colorectal cancer, coronary artery disease, hypertension, prostate cancer and type 2 diabetes.
This analysis estimated that it could meaningfully reduce premature mortality by identifying high-risk individuals earlier than standard screening alone.
That matters because population screening guidelines are designed around the average person.
Someone with a strong genetic predisposition can sit well outside that average while still meeting none of the criteria that would normally trigger closer monitoring.
The direction of travel is earlier detection, not just better detection
Researchers examining polygenic risk scores reflect a broader move away from waiting for symptoms before investigating. Genetic information and biomarkers may be used together to identify people who could benefit from earlier screening or closer observation.
A similar direction can be seen in cardiovascular medicine, where a 2025 review describes how biomarkers use data and more detailed patient profiling could support earlier risk assessment and more targeted prevention.
However, these developments are still making their way into routine clinical care. Further research, coordinated healthcare systems and fair access will be needed before their potential can be realised more widely.
Where Does Personalised Prevention Become Less Certain?
The performance of risk scores can vary between ancestries and populations, and laboratories do not yet use standard thresholds for what should be considered as ‘high risk’.
A score developed using data from one population may also be less accurate when applied to another.
A number on a report is not the same as a clinical decision.
Whether a particular result should lead to closer monitoring, lifestyle changes or a specialist referral still depends on a qualified professional considering the person’s wider health picture.
More Tools DoesNot Mean a More Coordinated Plan
It could be argued that precision prevention requires more than increasingly detailed data and improved technology.
The findings must also be communicated clearly and connected to a practical next step.
Without that next step, identifying a higher level of risk may cause anxiety or lead to unnecessary testing rather than better care.
The same principle applies when moving from diagnosis to intervention. Even a carefully selected supplement or therapy must take into account how an individual’s body absorbs and uses it.
At Nūūtro, personalised prevention starts with understanding what is actually happening in your body, rather than applying the same checklist to everyone.
If you are ready to explore personalised options that you may not know are available to you, you can schedule your 1:1 consultation to discuss your individual health profile.